Triglyceride otic formulations and uses thereof
Disclosed herein are triglyceride based formulations, compositions, and methods for the treatment of otic diseases and conditions. Such triglyceride based formulations and compositions are derived from long-chain triglycerides and allow for the delivery of a variety of therapeutic agents to the outer, middle, and/or inner ear.
1. An otic pharmaceutical formulation comprising:
a) a therapeutic agent, or pharmaceutically acceptable prodrug or salt thereof, and
b) triglycerides comprising long-chain fatty acids;
wherein the triglycerides are present in an amount that is sufficient to stabilize the therapeutic agent for injection into an ear, and wherein the otic pharmaceutical formulation is free of waxes and comprises at least about 50% by weight of the triglycerides.
2. The otic pharmaceutical formulation of claim 1 , wherein the triglycerides are present in an amount that is sufficient to provide sustained release of the therapeutic agent.
3. The otic pharmaceutical formulation of claim 1 , wherein the triglycerides are derived from glycerol and at least two long-chain fatty acids.
4. The otic pharmaceutical formulation of claim 3 , wherein the long-chain fatty acids are tridecylic acid (tridecanoic acid), myristic acid (tetradecanoic acid), pentadecylic acid (pentadecanoic acid), palmitic acid (hexadecanoic acid), margaric acid (heptadecanoic acid), stearic acid (octadecanoic acid), nonadecylic acid (nonadecanoic acid), arachidic acid (eicosanoic acid), heneicosylic acid (heneicosanoic acid), behenic acid (docosanoic acid), tricosylic acid (tricosanoic acid), lignoceric acid (tetracosanoic acid), pentacosylic acid (pentacosanoic acid), cerotic acid (hexacosanoic acid), heptacosylic acid (heptacosanoic acid), montanic acid (octacosanoic acid), nonacosylic acid (nonacosanoic acid), melissic acid (triacontanoic acid), henatriacontylic acid (henatriacontanoic acid), lacceroic acid (dotriacontanoic acid), psyllic acid (tritriacontanoic acid), geddic acid (tetratriacontanoic acid), ceroplastic acid (pentatriacontanoic acid), hexatriacontylic acid (hexatriacontanoic acid), heptatriacontanoic acid (heptatriacontanoic acid), octatriacontanoic acid, a-linolenic acid, stearidonic acid, eicosapentaenoic acid, docosahexaenoic acid, linoleic acid, g-linolenic acid, dihomo-y-linolenic acid, arachidonic acid, docosatetraenoic acid, palmitoleic acid, vaccenic acid, paullinic acid, oleic acid, elaidic acid, gondoic acid, erucic acid, nervonic acid, mead acid, or a combination thereof.
5. The otic pharmaceutical formulation of claim 1 , wherein the otic pharmaceutical formulation comprises between about 50% to about 99.99% by weight of the triglycerides.
6. The otic pharmaceutical formulation of claim 1 , wherein the otic pharmaceutical formulation further comprises at least one viscosity modulating agent.
7. The otic pharmaceutical formulation of claim 6 , wherein the at least one viscosity modulating agent is silicon dioxide, povidone, carbomer, poloxamer, or a combination thereof.
8. The otic pharmaceutical formulation of claim 6 , wherein the otic pharmaceutical formulation comprises between about 0.01% to about 20% by weight of the at least one viscosity modulating agent.
9. The otic pharmaceutical formulation of claim 1 , wherein the otic pharmaceutical formulation has a viscosity between about 10 cP to about 10,000 cP.
10. The otic pharmaceutical formulation of claim 1 , wherein the otic pharmaceutical formulation has an injectability of at least about 750 g.
11. The otic pharmaceutical formulation of claim 1 , wherein the therapeutic agent is an immunomodulating agent, an aural pressure modulating agent, a corticosteroid, an antimicrobial agent, an otic neurotrophic factor, an antagonist of truncated TrkC or truncated TrkB, a non-natural TrkB or Trk C agonist, or a WNT modulator.
12. The otic pharmaceutical formulation of claim 11 , wherein the therapeutic agent is dexamethasone, ciprofloxacin, or gacyclidine.
13. The otic pharmaceutical formulation of claim 11 , wherein the otic neurotrophic factor is selected from brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), glial cell-line derived neurotrophic factor (GDNF), neurotrophin-3, neurotrophin-4, fibroblast growth factor (FGF), insulin-like growth factor (IGF), epidermal growth factor (EGF), platelet-derived growth factor (PGF), and a combination thereof.
14. The otic pharmaceutical formulation of claim 1 , wherein the otic pharmaceutical formulation comprises between about 0.01% to about 20% by weight of the therapeutic agent, or pharmaceutically acceptable prodrug or salt thereof.
15. The otic pharmaceutical formulation of claim 1 , wherein the therapeutic agent is released from the formulation for a period of at least 1 day.
16. The otic pharmaceutical formulation of claim 1 , wherein the otic pharmaceutical formulation is free or substantially free of water, C1-C6 alcohols or C1-C6 glycols, C1-C4 alcohols or C1-C4 glycols, or any combination thereof.
17. The otic pharmaceutical formulation of claim 1 , further comprising cholesterol.
18. The otic pharmaceutical formulation of claim 17 , wherein the otic pharmaceutical formulation comprises between about 0.01% to about 20% by weight of the cholesterol.
19. The otic pharmaceutical formulation of claim 1 for use in the treatment of an otic disease or condition associated with the outer, middle, and/or inner ear.
20. A method of treating an otic disease or condition in a subject in need thereof, the method comprising administering to the subject the otic pharmaceutical formulation of claim 1 .